Comparison
Hexarelin vs. SNAP-8
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Cosmetic
CAS no.
140703-51-1
868844-74-0
Molecular weight
887.05 g/mol
1075.16 g/mol
Half-life
0.9 h
no data
Sequence
His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2Mechanism of action
Hexarelin
Hexarelin is a synthetic analog of the GHRP-6 family binding both the GH secretagogue receptor (GHSR-1a) and CD36. GHSR activation in the pituitary releases pulsatile growth hormone. Via CD36 in endothelium and myocardium, cardioprotective effects have been described in animal studies.
SNAP-8
SNAP-8 is an octapeptide variant of Argireline. The sequence corresponds to the N-terminus of the SNAP-25 protein. As with Argireline, the postulated mechanism is competitive inhibition of the SNARE complex needed for acetylcholine vesicle fusion at the neuromuscular endplate. According to the manufacturer the two extra C-terminal amino acids increase SNARE-complex affinity — there are individual industry studies on this but no independent systematic confirmation.
Evidence base
Highest evidence
Human trial
Human trial
Studies
4
3
of which in humans
3
1
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
1